Starpharma Holdings Ltd
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurr… Read more
Starpharma Holdings Ltd (SPHRY) - Total Assets
Latest total assets as of June 2025: $25.42 Million USD
Based on the latest financial reports, Starpharma Holdings Ltd (SPHRY) holds total assets worth $25.42 Million USD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Starpharma Holdings Ltd - Total Assets Trend (2014–2025)
This chart illustrates how Starpharma Holdings Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Starpharma Holdings Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Starpharma Holdings Ltd's total assets of $25.42 Million consist of 88.8% current assets and 11.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 60.6% |
| Accounts Receivable | $4.04 Million | 15.9% |
| Inventory | $1.92 Million | 7.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Starpharma Holdings Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Starpharma Holdings Ltd's current assets represent 88.8% of total assets in 2025, an increase from 77.6% in 2014.
- Cash Position: Cash and equivalents constituted 60.6% of total assets in 2025, down from 65.2% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 20.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 15.9% of total assets.
Starpharma Holdings Ltd Competitors by Total Assets
Key competitors of Starpharma Holdings Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Starpharma Holdings Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Starpharma Holdings Ltd generates 0.19x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Starpharma Holdings Ltd is currently not profitable relative to its asset base.
Starpharma Holdings Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.32 | 4.94 | 5.48 |
| Quick Ratio | 3.95 | 4.58 | 5.40 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $17.33 Million | $ 26.26 Million | $ 29.98 Million |
Starpharma Holdings Ltd - Advanced Valuation Insights
This section examines the relationship between Starpharma Holdings Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.01 |
| Latest Market Cap to Assets Ratio | 5.95 |
| Asset Growth Rate (YoY) | -30.9% |
| Total Assets | $25.42 Million |
| Market Capitalization | $151.17 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Starpharma Holdings Ltd's assets at a significant premium ( 5.95x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Starpharma Holdings Ltd's assets decreased by 30.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Starpharma Holdings Ltd (2014–2025)
The table below shows the annual total assets of Starpharma Holdings Ltd from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $25.42 Million | -30.95% |
| 2024-06-30 | $36.81 Million | -29.32% |
| 2023-06-30 | $52.09 Million | -21.29% |
| 2022-06-30 | $66.17 Million | -9.64% |
| 2021-06-30 | $73.24 Million | +87.41% |
| 2020-06-30 | $39.08 Million | -20.02% |
| 2019-06-30 | $48.86 Million | -16.50% |
| 2018-06-30 | $58.51 Million | -12.13% |
| 2017-06-30 | $66.59 Million | +12.79% |
| 2016-06-30 | $59.04 Million | +19.44% |
| 2015-06-30 | $49.43 Million | +34.09% |
| 2014-06-30 | $36.86 Million | -- |